The University of Melbourne and radiopharmaceutical manufacturer Cyclotek have opened the Laboratory for Advanced Radiochemical Science (LARS), a new facility designed to accelerate the development of next-generation cancer diagnostics and therapies.
Located at the University’s Parkville campus in Australia, LARS brings together leading research and student training with advanced manufacturing of molecular targeted therapies, helping translate new discoveries into clinical and commercial outcomes.
The partnership strengthens Australia’s sovereign capability in radiopharmaceuticals and supports a growing pipeline of clinical trials and industry collaboration.
Cyclotek supports more than 150,000 patient procedures annually across Australia and New Zealand and works with a broad network of clinical and research partners.
LARS will support new dynamic University and industry partnerships with a goal to improve access to advanced radionuclide-based diagnostics and therapies.
Dr James Glasgow, CEO of Cyclotek, said the facility strengthens the company’s role in translating research into practice. “This partnership allows us to take innovation beyond the lab, into clinical trials, manufacturing and patient care. It also strengthens Australia’s position as a partner for global radiopharmaceutical and device development”, said Dr Glasgow.
